Physician profile
Bobby Khan
NPI 1649565292
$1,092.42
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $183 · 2024: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $416.07 | 2019-2020 | |
| Pfizer INC. | $161.17 | 2019-2020 | |
| Novo Nordisk INC | $154.74 | 2019-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $90.72 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.54 | 2019-2020 | |
| Amgen INC. | $61.57 | 2019 | |
| Lilly USA, LLC | $25.23 | 2019 | |
| Merck Sharp & Dohme LLC | $23.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.01 | 2024 | |
| Sumitomo Pharma America, INC. | $21.49 | 2024 | Gemtesa |
| Mylan Specialty L.P. | $16.55 | 2024 | Yupelri |
| Therapeuticsmd, INC. | $13.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.